STUDY OBJECTIVES: Pulmonary involvement is a major cause of morbidity and mortality in patients with sickle cell disease (SCD). Although a high prevalence of airway hyperresponsiveness (AHR) has been reported, there are no studies demonstrating the relationship between AHR and acute chest syndrome (ACS) in adults with SCD. We investigated AHR prevalence, lung function abnormalities, and the relationships of these variables with ACS in SCD patients. METHOD: Thirty-one adult patients without asthmatic symptoms were compared with 31 matched controls. Expiratory flow rates, lung volumes, carbon monoxide diffusion capacity (DLCO), and methacholine provocation test (MPT) results were assessed. RESULTS: Forced vital capacity (FVC), forced expiratory volume in one second, forced expiratory flow rate at 25% to 75% of FVC (FEF(25%-75%)), peak expiratory flow rate, total lung capacity, and DLCO values were significantly lower in the patient group than in the controls. No significant difference in pulmonary function test results was found between patients with and without a history of ACS. Fifteen patients with SCD (48%) and only 5 controls (16%) had AHR (p = 0.007). A significant correlation was found between the number of ACS episodes and MPT positivity (r = 0.379, p = 0.035). The FEF(25%-75%) values were significantly lower in patients with positive MPT results than in patients with negative MPT results (p = 0.027). CONCLUSION: The prevalence of AHR was high in adult patients with SCD. A significant correlation was found between AHR and recurrent ACS episodes. Anti-inflammatory controller agents can be used routinely to decrease pulmonary morbidity associated with SCD, even in the absence of asthmatic symptoms.
STUDY OBJECTIVES: Pulmonary involvement is a major cause of morbidity and mortality in patients with sickle cell disease (SCD). Although a high prevalence of airway hyperresponsiveness (AHR) has been reported, there are no studies demonstrating the relationship between AHR and acute chest syndrome (ACS) in adults with SCD. We investigated AHR prevalence, lung function abnormalities, and the relationships of these variables with ACS in SCDpatients. METHOD: Thirty-one adult patients without asthmatic symptoms were compared with 31 matched controls. Expiratory flow rates, lung volumes, carbon monoxide diffusion capacity (DLCO), and methacholine provocation test (MPT) results were assessed. RESULTS: Forced vital capacity (FVC), forced expiratory volume in one second, forced expiratory flow rate at 25% to 75% of FVC (FEF(25%-75%)), peak expiratory flow rate, total lung capacity, and DLCO values were significantly lower in the patient group than in the controls. No significant difference in pulmonary function test results was found between patients with and without a history of ACS. Fifteen patients with SCD (48%) and only 5 controls (16%) had AHR (p = 0.007). A significant correlation was found between the number of ACS episodes and MPT positivity (r = 0.379, p = 0.035). The FEF(25%-75%) values were significantly lower in patients with positive MPT results than in patients with negative MPT results (p = 0.027). CONCLUSION: The prevalence of AHR was high in adult patients with SCD. A significant correlation was found between AHR and recurrent ACS episodes. Anti-inflammatory controller agents can be used routinely to decrease pulmonary morbidity associated with SCD, even in the absence of asthmatic symptoms.
Authors: Karl P Sylvester; Richard A Patey; Simon Broughton; Gerrard F Rafferty; David Rees; Swee Lay Thein; Anne Greenough Journal: Pediatr Pulmonol Date: 2007-02
Authors: Elisa Cristina Vendramini; Elcio O Vianna; Ivan De Lucena Ðngulo; Flavia Bueno De Castro; José A B Martinez; João Terra-Filho Journal: Am J Med Sci Date: 2006-08 Impact factor: 2.378
Authors: Karl P Sylvester; Richard A Patey; Peter Milligan; Gerrard F Rafferty; Simon Broughton; David Rees; Swee Lay Thein; Anne Greenough Journal: J Pediatr Date: 2006-07 Impact factor: 4.406
Authors: Biree Andemariam; Alexander J Adami; Anurag Singh; Jeffrey T McNamara; Eric R Secor; Linda A Guernsey; Roger S Thrall Journal: Transl Res Date: 2015-03-16 Impact factor: 7.012
Authors: Shaina M Willen; Robyn Cohen; Mark Rodeghier; Fenella Kirkham; Susan S Redline; Carol Rosen; Jane Kirkby; Michael R DeBaun Journal: Am J Hematol Date: 2018-01-25 Impact factor: 10.047
Authors: Marthe-Sandrine Eiymo Mwa Mpollo; Eric B Brandt; Shiva Kumar Shanmukhappa; Paritha I Arumugam; Swati Tiwari; Anastacia Loberg; Devin Pillis; Tilat Rizvi; Mark Lindsey; Bart Jonck; Peter Carmeliet; Vijay K Kalra; Timothy D Le Cras; Nancy Ratner; Marsha Wills-Karp; Gurjit K Khurana Hershey; Punam Malik Journal: J Clin Invest Date: 2015-12-21 Impact factor: 14.808
Authors: Jeffrey A Glassberg; Annie Chow; Juan Wisnivesky; Ronald Hoffman; Michael R Debaun; Lynne D Richardson Journal: Br J Haematol Date: 2012-09-12 Impact factor: 6.998
Authors: Najibah A Galadanci; Wayne H Liang; Aisha A Galadanci; Muktar H Aliyu; Binta W Jibir; Ibraheem M Karaye; Baba P Inusa; Sten H Vermund; Robert C Strunk; Michael R DeBaun Journal: J Pediatr Hematol Oncol Date: 2015-01 Impact factor: 1.289